FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n \n \n \n FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n TORONTO\n \n ,\n \n April 5, 2021\n \n /CNW/ - On\n \n Tuesday, March 30, 2021\n \n ,\n \n Anthony Durkacz\n \n , a founding director and member of the group of concerned shareholders, which also includes founding shareholder\n \n Zeeshan Saeed\n \n , (the \"\n \n Concerned Shareholders\n \n \") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (the \"\n \n Company\n \n \" or \"\n \n FSD\n \n \") received a Notice of Appeal from FSD (the \"\n \n Appeal\n \n \") of the\n \n March 5, 2021\n \n decision (the \"\n \n Decision\n \n \") of the Ontario Superior Court of Justice (Commercial List) (the \"\n \n Court\n \n \"). The Decision, which resulted from an application to the Court brought by Mr. Durkacz on behalf of the Concerned Shareholders, ordered the Company to accelerate the date of its previously called annual shareholders' meeting (the \"\n \n Meeting\n \n \") from\n \n June 29, 2021\n \n to\n \n May 14, 2021\n \n , retain an independent chair to preside over the Meeting and prevent Dr.\n \n Raza Bokhari\n \n and other directors from voting recently issued shares (the \"\n \n Order\n \n \").\n \n \n Among other things, FSD's Appeal is seeking to delay the date of the Meeting to\n \n June 29, 2021\n \n and remove voting restrictions that the Order attached to shares issued since\n \n January 4, 2021\n \n to Dr.\n \n Raza Bokhari\n \n , Stephen Buyer,\n \n Robert Ciaruffoli\n \n ,\n \n James Datin\n \n ,\n \n Gerald Goldberg\n \n and\n \n Larry Kaiser\n \n and any entities related to any of them.\n \n \n \"This is an entirely unjustified waste of FSD's money,\" said\n \n Anthony Durkacz\n \n , one of the Concerned Shareholders. \"FSD management resisted our proposed shareholder meeting date of\n \n March 31, 2021\n \n on the basis that the company needed to receive its audited financial statements for the 2020 financial year and wanted to avoid the expense of hol...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B